Today: 1 May 2026
Nasdaq Partners With Kraken on Tokenized Stocks, Eyes 2027 Launch

Nasdaq Partners With Kraken on Tokenized Stocks, Eyes 2027 Launch

NEW YORK, March 9, 2026, 10:33 (EDT)

Nasdaq announced Monday it’s developing a new system for tokenized shares—those built on blockchain technology—and has enlisted Payward, the company behind crypto exchange Kraken, to help create the link between established stock markets and blockchain platforms.

This is significant at this moment, with a top U.S. exchange stepping further into tokenized equities only days after banking regulators decided lenders won’t face additional capital requirements for blockchain-based securities. SEC staff, back in January, stated that tokenized shares may be handled as traditional ones provided holders retain essentially the same rights and privileges.

Tokenization, basically, means converting an asset—like a share or bond—into a token on the blockchain. Nasdaq’s setup aims to let issuers retain control of things like proxy voting, dividends, and other actions, while tying blockchain data directly to the company’s official share ledger. Tal Cohen, president at Nasdaq, described the move as a step toward an “always-on financial ecosystem.” GlobeNewswire

Payward and Kraken plan to develop an equities transformation gateway using Kraken’s xStocks framework, aiming to let tokenized shares flow between regulated venues and public blockchains in jurisdictions where it’s allowed. Nasdaq is targeting the first half of 2027 for the launch. Arjun Sethi, co-CEO of Payward and Kraken, said the setup could open access in areas where “traditional distribution has been limited.” Kraken Blog

The Wall Street Journal says the framework is set to allow any willing issuer to join, even those that aren’t listed on Nasdaq. Kraken would handle distribution for customers across Europe and beyond the U.S. Token holders, according to the Journal, are slated to get governance rights mirroring those of traditional shareholders.

ICE, which owns the New York Stock Exchange, is pushing for regulatory sign-off on its blockchain-powered platform aimed at nonstop trading and settlement. Over in Europe, tokenized stocks are already live through Robinhood, Gemini, and Kraken. Coinbase and Dinari are moving forward with related offerings in the U.S.

Back in September, Nasdaq laid out its proposed regulatory approach in a filing to the SEC, seeking approval for listed stocks and exchange-traded products to trade either as traditional digital securities or as tokenized versions, all through Depository Trust & Clearing Corporation—the main U.S. clearing utility. Nasdaq’s filing made clear: tokenized instruments shouldn’t be considered on par with regular shares unless they offer identical material rights and protections.

But it’s still early days for the plan. Nasdaq’s September filing made clear that launching token-settled trading hinges on both SEC approval and the necessary market plumbing coming together. In January, SEC staff flagged concerns that certain third-party stock tokens could be classified as synthetic, price-linked products—not actual shares.

Stock Market Today

  • Cardano (ADA) Prospects: Governance Focus and Potential for Millionaire Returns
    April 30, 2026, 10:39 PM EDT. Cardano (ADA), a governance-focused cryptocurrency launched in 2017 by Ethereum co-founder Charles Hoskinson, once soared to $3.10 but now trades near $0.25. It uses an energy-efficient proof-of-stake blockchain, Ouroboros, enabling faster transaction speeds than Ethereum and requiring rigorous peer reviews for projects to enhance security and scalability. Despite this, its developer community remains small compared to Ethereum's. Cardano's unique governance approach and new features like the Midnight sidechain could attract regulated industries. However, to turn $10,000 into $1 million again, ADA's price must rise 100-fold to $25, pushing its market cap beyond Ethereum but below Bitcoin's. The path to such growth faces significant challenges amid market competition and adoption hurdles.

Latest article

Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

1 May 2026
Sandisk shares dropped about 6% in after-hours trading Thursday despite reporting fiscal Q3 revenue of $5.95 billion, up 251% from a year earlier, and net income of $3.62 billion. The company announced a $6 billion buyback and forecast Q4 revenue of up to $8.25 billion. Gross margin rose to 78.4%. Shares had closed at $1,096.51 before slipping to about $1,030.
Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

1 May 2026
Apple reported fiscal Q2 revenue of $111.2 billion and earnings of $2.01 per share, beating analyst estimates. The board approved a $100 billion share buyback and raised the dividend. Shares fell about 1% after hours as iPhone sales missed forecasts and chip supply remained tight. Investors are watching for clarity on AI strategy and the upcoming CEO transition to John Ternus.
Nvidia Stock Falls as Google and Amazon AI Chip Push Tests the AI Trade

Nvidia Stock Falls as Google and Amazon AI Chip Push Tests the AI Trade

30 April 2026
Nvidia shares dropped 4.6% to $199.57 Thursday as investors reacted to Alphabet and Amazon expanding sales of their own AI chips. Alphabet reported Google Cloud revenue up 63% and began selling TPU chips directly to customers. AMD and Broadcom shares rose 5.1% and 3.0%, respectively. Amazon said its Trainium chip line secured $225 billion in revenue commitments.
Day One Biopharmaceuticals, Inc. Buyout: Why Servier’s $2.5 Billion Ojemda Deal Matters Now
Previous Story

Day One Biopharmaceuticals, Inc. Buyout: Why Servier’s $2.5 Billion Ojemda Deal Matters Now

Capricor Therapeutics Stock Rises Ahead of March 12 Update as FDA Watch on Duchenne Drug Builds
Next Story

Capricor Therapeutics Stock Rises Ahead of March 12 Update as FDA Watch on Duchenne Drug Builds

Go toTop